Sign In
Buy NVS
$153.37
-0.680 (-0.441%)
At Close: Jul 13, 2026
How To Build A $50,000 Dividend Portfolio In Today's Market
01:45pm, Monday, 13'th Jul 2026
The Dividend Income Accelerator Portfolio emphasizes high-quality companies with sustainable dividends, strong balance sheets, and attractive valuations to optimize risk-adjusted returns. I prioritize
Novartis vs. Teva: Which Pharmaceutical Stock Is a Better Buy in 2026?
12:12pm, Thursday, 09'th Jul 2026
Novartis AG maintains a highly profitable portfolio of innovative medicines with significant net margins. Teva Pharmaceutical Industries is executing a turnaround focused on biosimilars and high-growt
Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?
08:15am, Thursday, 09'th Jul 2026
VHT offers broad diversification across 429 healthcare holdings, while PPH concentrates on 26 drugmakers for higher growth potential.
The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
12:36pm, Wednesday, 08'th Jul 2026
Markets are being tested again. The AI trade has spent the past several weeks under real pressure, with memory, semiconductor, and neocloud names selling off hard after an extraordinary first half.
Novartis' Pipeline Building Continues, Pelacarsen Readout Coming Soon
08:40am, Tuesday, 07'th Jul 2026
Novartis continues to favor in-licensing and bolt-on acquisitions. The Myricx Bio acquisition expands Novartis' ADC pipeline with novel NMTi payloads, but commercial impact is several years away. Avid
Novartis to Expand Oncology Pipeline With Myricx Bio Acquisition
03:41pm, Monday, 06'th Jul 2026
NVS plans to acquire Myricx Bio for up to $1.5 billion, adding novel ADC technology to expand its oncology pipeline and tumor targets.
Novartis to Buy Myricx Bio for Up to $1.5 Billion
01:52am, Monday, 06'th Jul 2026
The deal for the privately held U.K.-based biotechnology firm will help bolster Novartis's oncology capabilities.
Novartis to acquire UK-based Myricx Bio for up to $1.5 billion
01:26am, Monday, 06'th Jul 2026
Swiss drugmaker Novartis said on Monday it had agreed to pay up to $1.5 billion for U.K.-based biotechnology firm Myricx Bio in a deal expected to close in the second half of 2026.
NVS Gains EC Approval for SMA Therapy Itvisma in Broad Population
03:16pm, Thursday, 02'nd Jul 2026
Novartis wins EC approval for Itvisma, the first gene replacement therapy for a broad SMA population, expanding treatment options from newborns to adults.
3 European Stocks to Carry Investors Through the Back Half of 2026
11:05am, Wednesday, 01'st Jul 2026
The first half of the year is over, and it may surprise some investors that European stocks are nearly at parity with U.S. stocks. The tale of the tape as of June 30 tells the story:
Novartis Eyes $5 Billion Pluvicto Opportunity
08:34am, Thursday, 25'th Jun 2026
Novartis (NVS) is sitting at the center of a fast-growing oncology market as radioligand therapy gains momentum in cancer treatment. The therapy uses targeted r
Antares Therapeutics signs potential $1.9 billion cancer drug deal with Novartis
08:15am, Wednesday, 24'th Jun 2026
Antares Therapeutics said on Wednesday it entered a collaboration with Novartis that could be worth up to about $1.9 billion, aiming to develop therapies for historically hard-to-drug cancer tar
Antares Therapeutics Enters Agreement with Novartis to Discover, Develop and Commercialize First-in-Class Cancer Therapies
07:00am, Wednesday, 24'th Jun 2026
BOSTON--(BUSINESS WIRE)--Antares Therapeutics, Inc. (“Antares”), a biotechnology company developing first-in-class precision medicines for cancer and other serious diseases, today announced a stra
Biotech's Silent Resurgence (5-Year Base Breakout)
05:21pm, Tuesday, 23'rd Jun 2026
The biotech sector's fundamentals are shifting rapidly-and the smartest money on Wall Street is already quietly rotating into the sector.
Novartis' Rhapsido Meets Primary Goal in Phase III Skin Disorder Study
11:30am, Monday, 15'th Jun 2026
Novartis reports phase III RemIND success for Rhapsido in chronic inducible urticaria, showing higher response rates and supporting new filings.
